Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Atlassian Corporation PLC (TEAM) vs Tilray Brands Inc (TLRY) Price & Performance

Atlassian Corporation PLCTrade
Tilray Brands IncTrade

Price performance (Past 24H)

Key statistics

Atlassian Corporation PLC vs Tilray Brands Inc — how do they compare? Atlassian Corporation PLC trades at $206.11 (market cap $51.53B), while Tilray Brands Inc trades at $3.51 (market cap $530.54M). The key difference: Atlassian Corporation PLC is far larger — about 97.1× Tilray Brands Inc's market cap, and Atlassian Corporation PLC is trading nearer its 52-week high, Tilray Brands Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Atlassian Corporation PLC for 65 Days and Tilray Brands Inc for 31 Days on average.

TEAMTLRY
Market Cap
$51.53B$530.54M
Volume
2,904,5119,099,075
Sector
TechnologyHealth
52-Week High
$203.57$21.00
52-Week Low
$57.15$3.57
Typical Hold Time
65 Days31 Days
Enterprise Value
$51.52B$684.46M

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Atlassian Corporation PLC

Atlassian (TEAM) trades at $205.09, up 4.81% today, showing strong momentum with three consecutive quarterly earnings beats. The stock maintains a bullish technical signal with moving averages supporting upward momentum, though RSI suggests potential overbought conditions. Revenue growth remains robust at $5.22B for 2025, with improving margins despite negative net income. Recent news highlights accelerating cloud migration and AI adoption driving investor optimism.

Outlook remains positive with 69.77% analyst buy ratings and a $140B addressable market growing at 14% annually. Key risks include persistent negative profitability, high valuation multiples, and competitive pressures. The stock trades above consensus price target of $191.16, suggesting near-term consolidation potential despite long-term growth catalysts from AI and cloud expansion.

Tilray Brands Inc

Tilray Brands (TLRY) trades at $3.50, down 5.79% on the day and near its 52-week low. The stock shows bearish technical signals with negative moving averages and recent earnings misses across four consecutive quarters. Despite revenue growth to $821 million in 2025, the company reported a substantial net loss of $2.19 billion, driven by impairment charges and high operating costs. Analyst sentiment remains cautious with 65% hold ratings, though the consensus price target of $65.01 suggests significant potential upside from current levels.

The outlook remains challenging with persistent profitability issues and negative cash flow from operations. Investment opportunity exists if Tilray can achieve projected 2026 revenue growth to $915 million and reduce losses. Key risks include ongoing operational inefficiencies, competitive pressures in the cannabis market, and regulatory uncertainty. The stock's current valuation at 0.44 P/S and 0.33 P/B may attract value investors betting on a turnaround.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

TEAM
15% Buy85% Sell
Avg holding period · 65 Days
TLRY
54% Buy46% Sell
Avg holding period · 31 Days

Top news

Latest headlines on both assets

About Atlassian Corporation PLC

Atlassian produces software that helps teams work together more efficiently and effectively. The company provides project planning and management software, collaboration tools, and IT help desk solutions. The company operates in four segments: subscriptions (term licenses and cloud agreements), maintenance (annual maintenance contracts that provide support and periodic updates and are generally attached to perpetual license sales), perpetual license (upfront sale for indefinite usage of the software), and other (training, strategic consulting, and revenue from the Atlassian Marketplace app store). Atlassian was founded in 2002 and is headquartered in Sydney.

Read more on TEAM →

About Tilray Brands Inc

Tilray is a Canadian company that grows and sells medical and recreational cannabis. In 2021, Aphria acquired Tilray in a reverse merger and adopted the Tilray name. Most of its sales come from Canada and international medical cannabis exports, while its U.S. business focuses on CBD products and alcohol.

Read more on TLRY →